Dose-dependent teratogenicity of valproate in mono- and polytherapy An observational study
Torbjorn Tomson, Dina Battino, Erminio Bonizzoni, John Craig, Dick Lindhout, Emilio Perucca, Anne Sabers, Sanjeev V Thomas, Frank Vajda
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Awarded by Netherlands Epilepsy Foundation (NEF)
EURAP has received financial support from the following pharmaceutical companies: Bial, Eisai, GlaxoSmithKline, Novartis, UCB, Janssen-Cilag, Pfizer, and Sanofi-Aventis. The following pharmaceutical companies have continued to provide financial support after 2010: Bial, Eisai, GlaxoSmithKline, Novartis, and UCB. Further financial support has been provided from Netherlands Epilepsy Foundation (NEF) grant 03-18 (Dr. Lindhout) and from Stockholm County Council, ALF (Dr. Tomson). The funding organizations had no influence on the conduct of the study, analysis, interpretation, writing of the manuscript, or the decision to publish the results. The Australian Pregnancy Register has received funding from Sanofi/Genzyme, UCB, Janssen, SciGen, Eisai, Australian National Health and Medical Research Council, Epilepsy Society of Australia, Royal Melbourne Hospital Medical Research Foundation, and Epilepsy Action.